Investment Rating - The report maintains a "Buy" rating for Meituan with a target price of 215.76 HKD [2][12][11] Core Insights - Overall performance exceeded expectations with Q3 2024 revenue of 936 billion CNY, a year-on-year increase of 22.4%, surpassing Bloomberg's consensus estimate of 920 billion CNY [1] - Adjusted operating profit for Q3 2024 was 136 billion CNY, exceeding the expected 112 billion CNY, with an operating profit margin of 14.5% [1] - Adjusted net profit reached 128 billion CNY, above the expected 118 billion CNY, with a net profit margin of 13.7% [1] Summary by Sections Financial Performance - Q3 2024 revenue was 936 billion CNY, with a year-on-year growth of 22.4% [1] - Adjusted operating profit was 136 billion CNY, with an operating profit margin of 14.5% [1] - Adjusted net profit was 128 billion CNY, with a net profit margin of 13.7% [1] Core Local Business - Revenue from core local business was 694 billion CNY, a year-on-year increase of 20.2% [1] - Adjusted operating profit for this segment was 146 billion CNY, exceeding expectations [1] - The operating profit margin improved by 3.5 percentage points year-on-year to 21.0% [1] New Business Developments - New business revenue reached 242 billion CNY, a year-on-year increase of 28.9% [1] - Operating loss narrowed to 10 billion CNY, with a loss rate improvement to 4.2% [1] - The report highlights ongoing efforts in overseas markets and community group buying as potential growth areas [1] Future Outlook - The report projects revenue growth for 2024 to reach 1,670 billion CNY, with adjusted net profit expected to be 39,041 million CNY [6][12] - The target price reflects a valuation of 13,130 billion HKD for the company [12]

Investment Rating - Maintain "Buy" rating for the company [2][4] Core Views - The company maintains a positive store expansion pace, focusing on mid-to-high-end brands, increasing penetration in lower-tier cities, and enhancing business travel cooperation and member loyalty [4] - Domestic RevPAR is under pressure due to a high base effect from the previous year, with OCC showing resilience but ADR declining significantly [4] - The company expects 2024E/2025E/2026E revenues of 23.7/25.8/28.0 billion RMB, with YoY growth of 8.2%/9.1%/8.3%, and net profits of 3.7/4.4/4.8 billion RMB, with YoY changes of -9.3%/+17.4%/+11.2% [4] - The current stock price corresponds to 2024E/2025E/2026E P/E ratios of 19/16/15x [4] Financial Performance - 2024Q3 revenue reached 6.44 billion RMB, up 2.4% YoY, with domestic self-operated, domestic franchised, overseas self-operated, and overseas franchised revenues at 2.461, 2.568, 1.229, and 0.034 billion RMB, respectively [4] - Adjusted EBITDA for 2024Q3 was 2.11 billion RMB, down 9.5% YoY, with domestic and overseas segments contributing 2.09 and 0.02 billion RMB, respectively [4] - Adjusted EBITDA margin was 32.8%, down 4.3 ppts YoY and 0.4 ppts QoQ [4] - Adjusted net profit was 1.37 billion RMB, down 10.8% YoY [4] Operational Metrics - Domestic RevPAR, ADR, and OCC for 2024Q3 were 256 RMB, 301 RMB, and 84.9%, down 8.1%, 7.0%, and 1.0 ppts YoY, respectively [4] - Overseas RevPAR, ADR, and OCC for 2024Q3 were 82 EUR, 117 EUR, and 69.8%, up 3.7%, 2.5%, and 0.8 ppts YoY, respectively [4] - The company opened 790 new domestic stores in 2024Q3, with the full-year store opening guidance raised from 2,200 to 2,400 stores [4] - Total store count reached 10,845 by the end of 2024Q3, with over 800 new contracts signed during the quarter [4] Financial Projections - 2024E/2025E/2026E revenues are projected at 23.7/25.8/28.0 billion RMB, with YoY growth of 8.2%/9.1%/8.3% [5] - 2024E/2025E/2026E net profits are projected at 3.7/4.4/4.8 billion RMB, with YoY changes of -9.3%/+17.4%/+11.2% [5] - 2024E/2025E/2026E EBITDA is projected at 6.78/7.51/8.17 billion RMB, with YoY changes of -0.8%/+10.8%/+8.7% [5] - 2024E/2025E/2026E EPS is projected at 1.16/1.37/1.52 RMB [5]

Investment Rating - The report does not explicitly state an investment rating for the company [2]. Core Insights - The company, Jiufang Zhitu Holdings, is a leading service provider in stock investment during the live broadcast era, focusing on intelligent investment advisory and fintech solutions [2]. - The company leverages advanced technologies such as big data, artificial intelligence (AI), and machine learning to create efficient and precise investment decision support systems [2]. - Jiufang Zhitu primarily serves affluent individual investors, providing personalized and professional services that benefit from the current retail investor-driven market [2]. Summary by Relevant Sections Business Model - Jiufang Zhitu Holdings has a mature business model that includes: 1. Intelligent investment advisory services that help individual investors create personalized investment plans, optimize asset allocation, reduce risks, and achieve better returns [4]. 2. Wealth management services for high-net-worth clients and institutions, covering asset allocation, investment portfolio management, and risk control, enhanced by AI technology [4]. 3. Financial data analysis and research, providing accurate market forecasts and investment analysis reports to assist clients in making informed investment decisions [4]. 4. Integration of AI with quantitative trading strategies, offering various automated trading tools and systems for efficient trade execution [4]. Market Conditions - Since late September, the Chinese capital market has shown signs of recovery, leading to a significant increase in trading volume and investor interest in stocks [8]. - The company has capitalized on this business development window, resulting in rapid growth in order numbers [8]. - The company’s performance is expected to improve significantly due to its rigid cost structure primarily consisting of R&D and marketing expenses, which allows it to maintain customer retention even during market fluctuations [8]. Financial Projections - The company’s operating revenue is projected to grow from 1,850.1 million HKD in the fiscal year ending December 31, 2022, to 2,670.5 million HKD by 2026, reflecting a compound annual growth rate (CAGR) of approximately 9.76% [9]. - Net profit is expected to recover from a significant decline in 2023 to 378 million HKD by 2026, indicating a strong rebound [9]. - Earnings per share (EPS) is forecasted to increase from 0.45 HKD in 2023 to 0.88 HKD in 2026, demonstrating a positive growth trajectory [9].

Investment Rating - The report initiates coverage on Aikang Medical (1789 HK) with a "Buy" rating and a target price of HKD 6 8 [1][2] Core Views - Aikang Medical is positioned as a leading domestic orthopedic joint company with strong performance in the national joint procurement program The company is expected to see accelerated revenue growth in 2025 as the impact of industry anti-corruption measures subsides and joint procurement risks are cleared [1] - The company is a pioneer in applying metal 3D printing to orthopedic implants and is leveraging technologies such as 3D printing ICOS and surgical robots to build a digital orthopedic platform which will help expand its presence in the mid-to-high-end market [1] - The orthopedic industry is under short-term pressure due to anti-corruption measures but will benefit in the long term from a large patient base increasing surgical penetration rates and domestic substitution [1] - Aikang Medical's core products have cleared procurement risks and the company is expected to see improved earnings visibility in 2025 with revenue growth potentially accelerating on a lower base in 2024 [1] Financial Projections - Revenue is projected to grow at a CAGR of 22% from 2023 to 2026E with 2024E and 2025E revenue expected to reach RMB 1 305 million and RMB 1 625 million respectively [3] - Net profit attributable to shareholders is forecasted to grow at a CAGR of 22 9% from 2023 to 2026E with 2024E and 2025E net profit expected to reach RMB 261 million and RMB 324 million respectively [3] - The company's PE ratio is expected to decline from 30 8x in 2023 to 17 5x in 2025E reflecting improved earnings growth [3] Industry Overview - The orthopedic industry continues to face short-term pressure from anti-corruption measures but is expected to recover in 2025 with revenue growth driven by a large patient base increasing surgical penetration rates and domestic substitution [16] - The industry saw a 3% YoY increase in revenue and a 1% YoY increase in net profit in 9M24 with signs of recovery in 1Q/2Q/3Q24 showing revenue growth of -9% +3% and +17% respectively [1] - Domestic substitution is expected to accelerate as foreign brands focus more on top-tier hospitals and reduce overall investment in China [1] Company-Specific Analysis - Aikang Medical's hip and knee joint products which contributed 85% of revenue in 1H24 performed well in the national joint procurement program with most products achieving price increases in the procurement [1] - The company is a leader in 3D printing technology for orthopedic implants and has developed the ICOS platform which offers customized solutions for patients and surgeons [2] - Aikang Medical has a dual-brand strategy in overseas markets with Aikang and JRI which provides a full product line advantage and potential for scale making international markets a key growth driver [2] Valuation and Target Price - The target price of HKD 6 8 is based on a 22x 2025E PE multiple in line with the company's historical average over the past three years [2] - The target price implies a 27% upside from the current price of HKD 5 4 [4]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 9.81 [4] Core Insights - The company has successfully renewed multiple products in the 2024 National Medical Insurance Directory, including Tevizo and HER2 monoclonal antibody, and has added a new indication for Tevizo in pediatric ITP [1][2] - The company is expected to see stable pricing for renewed products due to ongoing support from the medical insurance fund for innovative drugs, which will contribute to steady growth [1][2] - The company’s revenue is projected to grow by 12.8% in 2024 and 12.2% in 2025, with a corresponding net profit growth of 13.6% in 2025 [4] Summary by Sections - **Product Renewals and New Additions**: Tevizo and HER2 monoclonal antibody have been successfully renewed, with Tevizo gaining a new indication for pediatric ITP. The newly approved drug, sodium naftifine oral disintegrating tablet, has also entered the medical insurance directory [1][2] - **Pipeline Development**: The company is advancing its pipeline with several innovative products entering NDA or Phase III clinical trials, expected to be approved between 2025E and 2027E, providing new growth momentum [1][3] - **Sales and Market Expansion**: The company has established a robust sales capability across various channels, including blood, oncology, nephrology, and rheumatology, and is continuously enriching its innovative pipeline [3] - **Valuation Metrics**: The current market capitalization corresponds to 6.6 times the estimated PE for 2025, indicating an attractive valuation. The expected dividend payout ratio is 30%, with a projected dividend yield of 4.5% for 2025 [1][4]

Investment Rating - The report assigns a positive outlook on New World Development, indicating a new development cycle under the leadership of the new management team [2]. Core Insights - The appointment of Huang Shaomei as the CEO is expected to enhance the company's operations in both Hong Kong and mainland China, leveraging her extensive experience in real estate [2]. - The company has a land reserve of 3.72 million square meters, with 58% located in the Greater Bay Area and Yangtze River Delta, which supports its long-term growth strategy [2]. - The company has successfully divested non-core assets, with sales reaching HKD 8 billion in the fiscal year 2024 and projected to reach HKD 13 billion in fiscal year 2025 [2]. - Financing activities have been robust, with over HKD 50 billion in loans arranged and debt repayments completed in 2024, including the issuance of USD 400 million bonds [2]. - Recent policy adjustments in the real estate sector are expected to stabilize the mainland property market, particularly in the key regions of Guangzhou and Shanghai [2]. Summary by Sections Management Changes - Huang Shaomei has been appointed as the CEO, bringing over 20 years of real estate experience, which is anticipated to strengthen the company's strategic direction [2]. Financial Performance - The company reported a market capitalization of HKD 16.132 billion and a share price of HKD 6.41, with a 52-week high of HKD 11.98 and a low of HKD 6.20 [2]. Asset Management - The company is focusing on core assets in prime locations and has ongoing urban renewal projects, which differentiate its competitive position [2]. Financing Strategy - The company has completed significant financing arrangements, including long-term, low-interest loans totaling RMB 5.8 billion, with an average cost of 3.1% [2].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 26.82, indicating a potential upside of 28.0% from the current price of HKD 20.95 [5][6]. Core Insights - The company's revenue for the first three quarters of 2024 reached CNY 442.42 billion, a year-on-year decrease of 0.78%. The overall gross margin declined by 0.68 percentage points to 7.55%, and the net profit attributable to shareholders was CNY 5.279 billion, down 13.41% year-on-year [2]. - In Q3, the company experienced a revenue growth of 1.88% year-on-year, primarily due to a low base effect from the previous year, with a quarter-on-quarter growth of only 0.16%. The net profit for Q3 was CNY 1.575 billion, reflecting a year-on-year decrease of 20.94% [2]. Summary by Sections Pharmaceutical Distribution - The pharmaceutical distribution business showed a stable growth of 0.47% in the first half of the year. The company focused on key regions such as Jiangsu, Zhejiang, Shanghai, Central China, North China, and Guangxi, where revenue share has been increasing, leading to a growing market share. The direct sales to medical institutions slightly decreased, but retail direct sales increased due to the company's channel advantages [3]. Medical Device Distribution and Retail - The medical device distribution business faced significant pressure, with a revenue decline of 7.08% in the first half of the year. Although the distribution of medical consumables remained relatively stable, revenues from high-margin products like medical equipment and IVD test reagents decreased, impacting the overall gross margin [4]. - The retail business also suffered from a reduction in individual medical accounts and intensified competition, leading to a 6.43% year-on-year decline in retail revenue to CNY 16.6 billion. The company took measures such as closing loss-making stores, resulting in a narrowed loss for its retail subsidiary in Q3 [4]. Financial Metrics - The company has a total share capital of 3.121 billion shares and a market capitalization of HKD 64.75 billion. The stock has a 52-week high of HKD 23.65 and a low of HKD 16.02, with a net asset value per share of HKD 27.46 [5].

Investment Rating - The report initiates coverage on Aikang Medical (1789.HK) with a "Buy" rating and a target price of HKD 6.8, indicating a potential upside of 27% from the current price of HKD 5.4 [4][5]. Core Views - Aikang Medical, as a leading domestic orthopedic joint company, continues to demonstrate strong bidding performance in the ongoing national procurement of joint products, despite short-term industry disruptions due to anti-corruption measures. The company is expected to see improved visibility in revenue growth in 2025 as these risks clear [1][2]. - The long-term growth potential is supported by Aikang's focus on technological research and development, being the first in China to apply metal 3D printing in orthopedic implants. The company aims to leverage 3D printing, ICOS, and surgical robots to create a digital orthopedic platform, expanding its presence in the mid-to-high-end market [2][3]. Financial Forecasts and Valuation - Revenue is projected to grow from RMB 1,052 million in 2022 to RMB 1,990 million by 2026, with a compound annual growth rate (CAGR) of 22% from 2023 to 2026. The expected revenue growth rates for the years 2024, 2025, and 2026 are 19.3%, 24.5%, and 22.5%, respectively [3][14][97]. - The net profit is forecasted to increase from RMB 205 million in 2022 to RMB 399 million by 2026, with significant growth anticipated in 2025 [3][14][97]. - The report assigns a target price based on a price-to-earnings (PE) ratio of 22x for 2025E, aligning with the company's historical average [2][97]. Industry Overview - The orthopedic industry is currently facing short-term pressures due to anti-corruption measures, but it is expected to benefit in the long term from a large patient base, increasing surgical penetration rates, and domestic product substitution [1][16]. - The national procurement of orthopedic consumables has largely been implemented, with joint products being the first to undergo this process. The average price drop in the recent procurement round was around 6%, indicating a moderate impact on pricing [24][57]. - The domestic orthopedic implant market's localization rate is approximately 50%, with significant room for improvement as domestic brands gain market share through national procurement initiatives [27][29]. Product Development and Innovation - Aikang Medical has a comprehensive product layout in the joint category, having launched various generations of knee and hip joint replacement products since 2004. The company has also expanded its product line through strategic acquisitions, enhancing its technological capabilities and market reach [52][53]. - The introduction of the ICOS platform allows for customized orthopedic solutions, which is expected to drive sales in the mid-to-high-end market segment [62][64]. International Expansion - Aikang Medical employs a dual-brand strategy with Aikang and JRI in overseas markets, focusing on cost-effectiveness and stable product quality. The company aims to increase its overseas revenue contribution from 19% in 1H24 to over 30% in the medium to long term [93][94].

Investment Rating - The report maintains a "Buy" rating for Baidu Group-SW (09888) with a target price of HKD 137 [1] Core Views - Baidu's Q3 2024 total revenue was RMB 33.6 billion, down 3% YoY, with Non-GAAP net profit of RMB 5.9 billion, down 19% YoY [1] - Baidu Core revenue was RMB 26.5 billion, with online marketing revenue at RMB 18.8 billion, down 4% YoY due to macroeconomic challenges [1] - Non-online marketing revenue grew 12% YoY to RMB 7.7 billion, driven by AI Cloud, which contributed RMB 4.9 billion, up 11% YoY [1] - AI revenue accounted for 11% of total AI Cloud revenue, with iQIYI revenue at RMB 7.2 billion, down 10% YoY [1] - The company's strong technical advantages in AI infrastructure are expected to drive further growth in AI Cloud revenue [1] AI Cloud & ERNIE - Baidu expanded its ERNIE series with two enhanced lightweight models, Speed Pro and Lite Pro [1] - ERNIE processed approximately 1.5 billion API calls daily in November, up from 600 million in August, indicating strong market adoption [1] - ERNIE Agent's daily conversations reached 15 million, with monthly active users at 704 million, up 6% YoY [1] - AI-generated content in search results increased from 18% to 20%, with AI features covering nearly 70% of Baidu App's monthly active users [1] Profitability - Non-GAAP operating profit for Q3 2024 was RMB 7 billion, with an operating margin of 26% [1] - The company expects continued improvement in operating margins as user behavior on Baidu Search improves [1] Autonomous Driving - Baidu's autonomous driving service, Apollo Go, provided approximately 988,000 rides in Q3 2024, up 20% YoY [1] - As of October 28, 2024, Apollo Go has completed over 8 million rides, with the sixth-generation autonomous vehicle, Apollo RT6, priced competitively below USD 30,000 [1] Investment Recommendation - The report adjusts revenue forecasts for FY2024-2026 to RMB 1338/1476/1641 billion, with Non-GAAP operating profit adjusted to RMB 274/308/342 billion [1] - The target price of HKD 137 is based on a SOTP valuation, assigning 8x P/E for advertising, 3x P/S for cloud business, and 14x P/E for iQIYI's non-advertising revenue [1] - The "Buy" rating is maintained due to Baidu's ongoing AI transformation and investments in AI Cloud and autonomous driving [1]

Investment Rating - The report maintains a "Buy" rating for Meituan with a target price raised to HK$240.00 from HK$193.00, indicating a potential upside of 39% from the current price of HK$172.20 [2][3][10]. Core Insights - Meituan's 3Q24 performance showed stable and sustainable profit growth, with revenue and operating profit growth in the instant delivery segment outpacing order volume growth [6][10]. - The report highlights a healthy growth forecast for the dine-in and travel segments, with expected revenue and operating profit growth of 25% year-on-year in 4Q24 [7][10]. - The report emphasizes the improvement in profitability prospects for core local businesses, including food delivery and dine-in services, leading to a projected 23% year-on-year growth in operating profit for 2025 [10][18]. Financial Summary - Revenue for 2024 is projected at RMB 336,900 million, with an expected year-on-year growth of 22% [11][17]. - Adjusted EPS for 2024 is forecasted to be RMB 7.47, reflecting a 15% increase from previous estimates [9][17]. - The adjusted net income for 2024 is expected to reach RMB 47,348 million, with a net profit margin of 14.1% [11][17]. Segment Performance - The instant delivery segment reported a 14.5% year-on-year increase in order volume, with management projecting that flash purchase orders could eventually capture 10% of the Chinese e-commerce market [8][10]. - The dine-in and travel segment saw a 50% increase in order volume in 3Q24, with revenue growth of 25% year-on-year [10][11]. - New business losses narrowed to RMB 10 billion in 3Q24, down from RMB 13 billion in 2Q24, indicating a trend towards improved profitability [10][11]. Valuation - The report employs a sum-of-the-parts (SOTP) valuation approach, estimating the food delivery business at USD 78 billion and the dine-in and travel business at USD 49 billion, both based on a 15x P/E ratio for 2025 [18][20][22]. - The community e-commerce and local retail business is valued at USD 63 billion, using a 0.8x P/GMV multiple for 2025 [20][22].